|  |
| --- |
| **Supplemental Table 2**. Baseline cardiac functional parameters among the groups with or without ERK1/2 inhibitor |
|  |  |  |  |  | F values for two-way ANOVA |
| Parameters | KHB | KHB + CQ | KHB + SCH | KHB + CQ + SCH | Main effect | Main effect | Interaction |
| 　 | 　 | 　 | 　 | 　 | (CQ) | (SCH) | (CQ x SCH) |
| Coronary flow（ml/min） | 8.8 ± 0.9 | 10.1 ± 1.4 | 7.5 ± 1.3 | 9.5 ± 3.7 | 2.51 | 0.78 | 0.09 |
| Heart rate（bpm） | 186 ± 34 | 187 ± 7.5 | 181 ± 20 | 199 ± 21 | 0.71 | 0.09 | 0.57 |
| LVDP（mmHg） | 132 ± 18 | 122 ± 12 | 151 ± 23 | 134 ± 26 | 1.66 | 2.20 | 0.09 |
| +dpdt（×103 mmHg/s） | 3.0 ± 0.4 | 2.6 ± 0.1 | 3.2 ± 0.4 | 2.8 ± 0.6 | 3.35 | 0.55 | 0.01 |
| –dpdt（×103 mmHg/s） | 2.2 ± 0.6 | 2.0 ± 0.1 | 2.2 ± 0.3 | 2.1 ± 0.5 | 1.14 | 0.08 | 0.03 |
| RPP（×104 mmHg/min） | 2.4 ± 0.4 | 2.3 ± 0.3 | 2.7 ± 0.3 | 2.7 ± 0.7 | 0.13 | 2.17 | 0.10 |
| Values, mean ± SEM. n = 4 for each group. All P values by two-way ANOVA were not significant. |
| CQ, chloroquine; ERK, extracellular signal-regulated kinase; KHB, Krebs-Henseleit buffer; LVDP, left ventricular developed pressure; |
| RPP, rate pressure product; SCH, ERK inhibitor (SCH 772984) |